trial · primary record
Tislelizumab (BGB-A317)
MSI-H/dMMR Solid Tumors
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 200 |
| Primary completion | 2027-09 |
| Primary endpoint | Objective response rate assessed by Independent Review Committee per Response Evaluation Criteria in Solid Tumors Version 1.1 |
| Registry ID | NCT03736889 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:39.876Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03736889
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.